Contraceptive Implant Duration | How Long the Rod Works

The contraceptive implant is a small etonogestrel rod placed under the skin of the upper arm. In the United States, Nexplanon is approved for up to 5 years of use under its January 2026 FDA label. Approved duration can differ by country and product. Several cohort studies followed users beyond the original three-year label and have reported very low pregnancy rates in years four and five. Any decision to extend use beyond the labelled duration should be made with a clinician who knows your medical history and local guidance.

Check the approved duration for your implant in your country and confirm your replacement date with your clinician.

What the evidence says

A WHO led cohort reported no pregnancies among users who kept the etonogestrel implant in place into years four and five. You can read the study here: Ali et al., Contraception 2016. The authors concluded that effectiveness remained very high during those extra years, while noting that the number of users who continued beyond 3 years was modest.

Other observational work has also found very low pregnancy rates when the implant remains in place past the original three-year label. These data suggest that hormone release and ovulation suppression do not stop suddenly at 3 years. Hormone release falls over time, while studies assess how long contraceptive effectiveness is maintained.

Professional guidance reflects these findings but differs by region. The American College of Obstetricians and Gynecologists notes effectiveness for at least 4 years and reports no pregnancies in one study through 5 years. The UK licence also allows up to 5 years, confirmed in the CoSRH statement of 13 May 2026. In Australia, the consumer information reviewed for Implanon NXT still lists 3 years. The TGA has listed a five-year indication under evaluation; a proposed indication is not an approval. Check the current Australian product information and your replacement date with your clinician.

Why labels and guidelines can differ

Product labels are based on the evidence that manufacturers submit to regulators at the time of approval. If early trials only followed users for 3 years, the approved duration on the label will match that time period. Later studies may extend beyond that window, but labels do not always change quickly even when more data become available.

Guidelines from professional bodies, on the other hand, can incorporate newer cohort studies and life table analyses. This is why you may see a difference between the official label duration and what some guidance documents say about possible extended use. Clinicians are allowed to use medicines off label when it is supported by evidence and local standards, but they are expected to explain the uncertainty and document those decisions.

What this means in practice

• Arrange replacement by the end of the approved duration for your product and country. For US Nexplanon, the current FDA label specifies removal or replacement by the end of year five.
• If access to replacement is delayed, talk with your clinician about temporary backup methods and whether short term extension is reasonable in your situation. Do not assume there is a grace period beyond your product’s approved duration.
• Guidance from some professional bodies notes that weight alone is not a reason for early replacement, although data in people with very high BMI are limited. Your clinician may still factor body weight and other conditions into an individual plan.
• If you feel anxious about relying on off label duration, it may be more comfortable to use condoms or another backup method until you can replace the implant, even if the statistical risk appears low.

How the implant works, briefly

The rod releases etonogestrel, a progestogen. It mainly prevents ovulation and also thickens cervical mucus so that sperm are less likely to reach an egg. These effects are strongest soon after insertion and decline slowly over time as the hormone reservoir is used up.

In theory, as hormone levels fall, some ovulatory cycles could return before the label end date, and some users could still have suppressed ovulation after the label date. Real world studies that follow people over time help estimate how often ovulation resumes and how that translates into pregnancy rates in everyday use.

Questions to ask your clinician

If your implant is approaching its replacement date, these questions may help structure a discussion:

• What does local guidance at this clinic say about extended use of the etonogestrel implant?
• How long do you usually consider the implant to remain highly effective in people my age and with my health background?
• Is there any reason in my medical history that would make extended use less suitable for me?
• If replacement cannot happen straight away, what backup methods do you recommend until it is changed?

Hearing how your own service interprets the evidence can help you decide your replacement date under the current local product licence.

For broader context on methods and effectiveness, see Contraceptives and fertility.